Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
26 hedge funds and large institutions have $6.82M invested in Regulus Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 26 → 26 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.24% less ownership
Funds ownership: 48.01% → 47.77% (-0.24%)
38% less capital invested
Capital invested by funds: $11.1M → $6.82M (-$4.26M)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$24.1K |
| 2 |
LPL Financial
San Diego,
California
|
+$17.9K |
| 3 |
GC
Grimes & Company
Westborough,
Massachusetts
|
+$13.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.38K |
| 5 |
Renaissance Technologies
New York
|
+$5.29K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$58.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$48.6K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$9.02K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.19K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$398 |
RGLS Hedge Fund Activity: Q1 2023 in Review
26 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2023, worth a combined $6.82M — down 38% from $11.1M a quarter earlier.
Fund positioning in RGLS was balanced in Q1 2023: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 5 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $24.1K. The largest seller was BlackRock, cutting an estimated $58.3K.
- 26 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $6.82M of Regulus Therapeutics stock for Q1 2023, down 38% quarter-over-quarter.
- 4 funds opened new Regulus Therapeutics positions in Q1 2023 and 4 closed out, a net change of 0 holders.
- The largest Regulus Therapeutics buyer in Q1 2023 was Jane Street, an estimated $24.1K added.
- The largest Regulus Therapeutics seller in Q1 2023 was BlackRock, an estimated $58.3K sold.
Based on aggregated 13F filings for Q1 2023.